Results 121 to 130 of about 52,949 (209)

Synthesis of Quinazoline Derivatives and Mechanistic Approaches in Lung and Breast Cancers. [PDF]

Molecules
Kaya AZ, Tutuş B, Karaca Arpa Ş, Evren AE, Akalin Çiftçi G, Temel HE, Yurttaş L.   +6 more
europepmc   +1 more source

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. [PDF]

Signal Transduct Target Ther
Yu J, Xiong A, Wang Q, Chen J, Niu H, Zhou C, Tian P, Zhuang W, Li J, Wang J, Lu J, Gu K, Shi J, Guo J, Di Y, Lv D, Sun D, Cao L, Yang Z, Wu J, Miao L, Pan Y, Li C, Wu X, Yin J, Wang X, Sun M, He M, Cang S, Fang H, Chen P, Zhang M, Yang X, Zhao H, Feng J, Ma X, Hu S, Lu J, Zhao X, Zhuang Z, Sun Y, Sun X, Yu B, Zhu C, Chen J, Xu J, Wang K, Zhou C.   +47 more
europepmc   +1 more source

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer. [PDF]

Cancer Res Commun
Tan AC, Yeo JC, Alvarez JJS, Pang M, Guo YA, Hoo R, Takano AM, Ong BH, Goh D, Yeong J, Wu Z, Yuan J, Shathishwaran S, Sim NL, Chua KP, Tam WL, Wang LY, Lau DPX, Saw SP, Jain A, Lai GG, Tan WL, Ang MK, Ng QS, Kanesvaran R, Lim DW, Skanderup AJ, Tan DS.   +27 more
europepmc   +1 more source

Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes. [PDF]

Am J Cancer Res
Li F, Guo Y, Xu Z, Li W, Dong Y, Xu F.
europepmc   +1 more source

CDDO-Me Overcomes Gefitinib Resistance in NSCLC by Targeting the Src/STAT3 Axis to Induce Apoptosis and Pyroptosis. [PDF]

Int J Mol Sci
Li T, Du W, Wang R, Yu X, Zhang B, Wang W, Xu J, Cao H, Tang D, Liu N.   +9 more
europepmc   +1 more source

Antineoplastic Activity of the Combination Loratadine-Simvastatin-Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies. [PDF]

Cancers (Basel)
Raya-Bahena T, Rivera-Escobar RM, Hernández-Gallegos E, Jiménez-Salazar JE, Damián-Matsumura P, García-Quiroz J, Camacho J.   +6 more
europepmc   +1 more source

A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy. [PDF]

Cancer Med
Diao D, Tong Y, Zhai J, Mai S, Liu X, Rao X, Cai K.   +6 more
europepmc   +1 more source

Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China. [PDF]

Front Public Health
Chen P, Jiang Y, Chen Y, Luo S, Wu C, Tang Q, Zhang D, Wang Y, Ma J.   +8 more
europepmc   +1 more source

Health-Related Quality of Life and Cost-Effectiveness of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Monotherapy in Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Systematic Review. [PDF]

Cureus
Kumar S, Mudgal SK, Varikasuvu SR, Singh D, Singh H, Mahato S, Sarangi PK, Mondal H.   +7 more
europepmc   +1 more source

Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source